Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
NOCTURNAL REDUCTION OF BLOOD-PRESSURE AND THE ANTIHYPERTENSIVE RESPONSE TO A DIURETIC OR ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR IN OBESE HYPERTENSIVE PATIENTS
Autore:
WEIR MR; REISIN E; FALKNER B; HUTCHINSON HG; SHA L; TUCK ML;
Indirizzi:
UNIV MARYLAND HOSP,DIV NEPHROL,22 S GREENE ST BALTIMORE MD 21201 UNIV MARYLAND,SCH MED,DEPT MED,DIV NEPHROL BALTIMORE MD 21201 LOUISIANA STATE UNIV,MED CTR,NEPHROL SECT NEW ORLEANS LA 00000 MED COLL PENN & HAHNEMANN UNIV,DEPT PEDIAT PHILADELPHIA PA 00000 ZENECA PHARMACEUT INC WILMINGTON DE 00000 VAMC,DEPT MED SEPULVEDA CA 00000
Titolo Testata:
American journal of hypertension
fascicolo: 8, volume: 11, anno: 1998,
parte:, 1
pagine: 914 - 920
SICI:
0895-7061(1998)11:8<914:NROBAT>2.0.ZU;2-0
Fonte:
ISI
Lingua:
ENG
Soggetto:
SODIUM SENSITIVITY; NON-DIPPERS; MECHANISMS; VOLUME;
Keywords:
HYPERTENSION; OBESITY; AMBULATORY BLOOD PRESSURE; LISINOPRIL; HYDROCHLOROTHIAZIDE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
39
Recensione:
Indirizzi per estratti:
Citazione:
M.R. Weir et al., "NOCTURNAL REDUCTION OF BLOOD-PRESSURE AND THE ANTIHYPERTENSIVE RESPONSE TO A DIURETIC OR ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR IN OBESE HYPERTENSIVE PATIENTS", American journal of hypertension, 11(8), 1998, pp. 914-920

Abstract

During a 12-week, multicenter study to evaluate the efficacy and safety of lisinopril and hydrochlorothiazide (HCTZ) for the treatment of obesity-related hypertension, ambulatory blood pressure (ABP) monitoring was performed both at baseline and at study completion in 124 patients. Patients were randomized to three groups: placebo, lisinopril (10,20, or 40 mg/day), or HCTZ (12.5, 25, or 50 mg/day). All groups were matched with regard to sex, race, age, body mass index, and waist/hip ratio. The primary analysis of ABP data revealed that both lisinopril and HCTZ effectively lowered mean 24-h systolic (SBP) and diastolic (DBP) blood pressure compared with placebo, (mean change from baseline SBP/DBP: -12.0/-8.2, -10.6/-5.5, and -0.3/-0.5 mm Hg, respectively); however, lisinopril lowered DBP better than HCTZ (P <.05). Secondary analyses of groups revealed that men responded better to lisinopril than HCTZ (-11.9/-7.3 v -6.6/-3.5 mm Hg, respectively), whereas women responded well to both drugs. White patients responded better to lisinoprilthan HCTZ, whereas black patients showed a significant response to HCTZ only. Response to treatment was also influenced by patient classification of 24-h blood pressure profiles, ie, ''dipper'' or ''nondipper. '' Overall, the majority of obese hypertensives were nondippers. Nondippers (n = 82) responded well to both drugs (-10.4/-6.9 v -12.5/-5.7 mm Hg, P <.05 v placebo), whereas dippers (n 42) responded to lisinopril(-11.7/-9.4 mm Hg, P <.05 v placebo and HCTZ), but not HCTZ (-5.6/-4.1 mn Hg, P = NS v placebo). Results of 24-h ABP data show that both lisinopril and HCTZ are effective therapies for obesity-related hypertension and that response to treatment is influenced by sex, race, and dipper/nondipper status. Am J Hypertens 1998; 11:914-920. (C) 1998 American Journal of Hypertension, Ltd.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/11/20 alle ore 21:50:48